Skip to Main Content

An official website of the United States government

Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit  cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.

Principal Investigator
Name
LI LI
Institution
CASE WESTERN RESERVE UNIVERSITY
Position Title
-
Email
About this CDAS Project
Study
PLCO (Learn more about this study)
Project ID
2014-0157
Title
15-Hydroxyprostaglandin Dehydrogenase, NSAIDs, Vitamin D, and Coloretcal Neoplasia
Summary
Prostaglandin signaling pathway plays an important role in colon tumorigenesis. Inhibition of COX-2 with resultant decreased levels of prostaglandin E2 (PGE2) is a key mechanism underlying the colon chemo- preventive effects of non-steroidal anti-inflammatory drugs (NSAIDs). 15-hydroxyprostaglandin dehydrogenase (15-PGDH), a downstream metabolic antagonist of COX-2, has recently been established as a novel colon neoplasia suppressor. NSAIDs exert anti-neoplastic effects through a 'sandwiched' manner on the PGE2 pathway by concomitant suppression of COX-2 and up-regulation of 15-PGDH. Emerging evidence suggests that vitamin D also exerts anti-neoplastic effects through its actions on the PGE2 signaling pathway by down- regulating COX-2, up-regulating 15-PGDH, and inhibiting EP1-EP4, the receptors for PGE2. We have shown in a colon adenoma prevention trial that individuals who developed new adenomas while receiving celecoxib also had low colonic 15-PGDH expression levels. Furthermore, we have recently identified a SNP in the promoter region of 15-PGDH gene that is associated with both an increased risk of colon cancer and decreased colonic tissue expression of 15-PGDH in humans. These lead to our central hypothesis that 15-PGDH is a susceptibility gene for human colon neoplasia, and NSAIDs and circulating levels of vitamin D may interact with 15-PGDH to impact colon tumorigenesis. This proposal builds upon the PLCO trial and an established colon screening population in Cleveland, where normal colonic tissues from a subset of cases and controls are readily available. Specifically, Aim 1 uses a 3-stage design (discovery, tissue expression validation, and replication) to interrogate the entire 15-PGDH gene locus (spanning 100kb upstream and downstream) for colorectal neoplasia predisposing genetic variants of 15-PGDH. Aim 2 examines PE2 signaling pathway key gene expression levels in normal colonic tissues from a set of 309 adenoma cases and 327 controls, and assesses their associations with risk of colorectal adenoma. Aim 3 synthesizes SNP, gene expression, and exposure data to assess the joint effects of 15-PGDH, NSAIDs, and serum levels of vitamin D on risk of colorectal neoplasia. Our proposed study will provide novel insight into the etiological role of 15-PGDH in colon carcinogenesis, and will inform individualized strategies to maximize the 15-PGDH dependent chemoprevention effects of NSAIDs and vitamin D, and minimize the adverse gastrointestinal and cardiac effects that have thus far hampered population-wide use of NSAIDs for chemoprevention. PUBLIC HEALTH RELEVANCE: This study, building upon the large PLCO screening arm population and a Cleveland colonoscopy screening cohort, addresses the hypothesis that 15-PGDH is a novel susceptibility gene for human colon neoplasia, and genetic variants and tissue expression levels of 15-PGDH may work jointly with non-steroidal anti-inflammatory drug use (NSAIDs) and circulating levels of vitamin D to impact the development of early colorectal neoplasia.
Aims

-

Collaborators

-